Intraoperative Esketamine and Postpartum Depression Among Women With Cesarean Delivery: A Randomized Clinical Trial

作者：Li Ren, Ting Zhang, B Zou, Xiaomei Su, Y Tao, Jixing Yang, Fangfang Lv, Peining Li, Fei Peng, Guodong Wu · 发表于：Obstetric Anesthesia Digest · 年份：2025 · DOI：10.1097/01.aoa.0001171036.71757.fb · 被引用次数：1 · 研究领域：Maternal Mental Health During Pregnancy and Postpartum、Treatment of Major Depression、Neuroendocrine regulation and behavior

( JAMA Network Open . 2025;8(2):e2459331. doi: 10.1001/jamanetworkopen.2024.59331) Postpartum depression (PPD) is a widespread condition affecting about 17.7% of new mothers globally, with an even higher incidence of 21.4% reported in China. Cesarean birth (CB) appears to increase the risk of developing PPD compared to vaginal births. Given the growing recognition of esketamine, a derivative of ketamine, as a rapid-acting antidepressant, its potential use in PPD prevention has become a subject of interest. While prior randomized clinical trials (RCTs) have shown mixed results, there has been limited real-world evidence of its efficacy in typical clinical settings. The objective of this study was to examine the practical impact of esketamine in reducing the risk of PPD following CB.